arrow
F

Fozia Ahmed

Manchester University Hospitals NHS Foundation Trust
H指数:32
被引数:5,494

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Frailty and Effects of Semaglutide in Obesity-Related HFpEF

虚弱及司美格鲁肽在肥胖相关HFpEF中的效果

2025-09-150
OAAI
A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

一种新型治疗评分(QUAD评分),用于促进射血分数降低的心力衰竭的治疗优化

2025-09-080
OAAI
Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial
HEART
IF4.4
2025-02-120
PRE
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure

易患心力衰竭的患者进行增量穿梭步行测试的心率反应性,恢复和耐力

2024-08-110
OA
Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF)

优化心力衰竭途径以增强患者护理: 优化心力衰竭患者途径 (pro-hf) 的计划

2024-06-240
OA
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
HEART
IF4.4
2024-05-092
OAAI
The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron De ficiency, and Heart Failure With Reduced Ejection Fraction
2024-05-012
OAAI
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

射血分数保留的肥胖相关心力衰竭患者的Semaglutide与安慰剂: STEP-HFpEF和STEP-HFpEF DM随机试验的汇总分析

LANCET
IF88.5
2024-04-0157
OAAI
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
2023-09-21413
OA
Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial

经皮血运重建治疗缺血性左心室功能障碍后的心律失常和死亡: 来自REVIVED-BCIS2试验的预设分析

2023-09-1216
OAAI
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
2023-08-2782
OAAI